Page last updated: 2024-09-04

vatalanib and hts 466284

vatalanib has been researched along with hts 466284 in 1 studies

Compound Research Comparison

Studies
(vatalanib)
Trials
(vatalanib)
Recent Studies (post-2010)
(vatalanib)
Studies
(hts 466284)
Trials
(hts 466284)
Recent Studies (post-2010) (hts 466284)
276429843027

Protein Interaction Comparison

ProteinTaxonomyvatalanib (IC50)hts 466284 (IC50)
Chain A, TGF-beta receptor type IHomo sapiens (human)0.051
Chain A, TGF-beta receptor type IHomo sapiens (human)0.051
TGF-beta receptor type-1Homo sapiens (human)0.0522
TGF-beta receptor type-2Homo sapiens (human)0.4
Mitogen-activated protein kinase 14Homo sapiens (human)0.74
Mitogen-activated protein kinase kinase kinase 20Homo sapiens (human)1.4

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bockman, J; Rice, MC1

Other Studies

1 other study(ies) available for vatalanib and hts 466284

ArticleYear
Anticancer Drug Discovery and Development - SRI's Seventh Annual Summit.
    IDrugs : the investigational drugs journal, 2005, Volume: 8, Issue:10

    Topics: Angiogenesis Inhibitors; Benzamides; Chemistry, Pharmaceutical; Clinical Trials as Topic; Cooperative Behavior; Diphenylamine; Drug Industry; Drugs, Investigational; Humans; Lenalidomide; Marketing; Phthalazines; Piperazines; Protein Serine-Threonine Kinases; Pyrazoles; Pyridines; Quinolines; Receptor Protein-Tyrosine Kinases; Receptor, Transforming Growth Factor-beta Type II; Receptors, Transforming Growth Factor beta; Stem Cell Factor; Thalidomide; Thiophenes; Vascular Endothelial Growth Factor A

2005